AIM
BTAI icon

Anchor Investment Management’s BioXcel Therapeutics BTAI Stock Holding History

Anchor Investment Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed -$1.03K – 1015
2021
Q3 		$1.03K Buy
+2
New +$879 ﹤0.01% 901

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Anchor Investment Management's BTAI Position: Q4 2021 in Review

Anchor Investment Management sold out of BioXcel Therapeutics (BTAI) in Q4 2021, closing a stake of 2 shares — an estimated $1.03K sold.

Anchor Investment Management first reported a position in BTAI in Q3 2021 and held it in 1 quarter. The position peaked at $1.03K in Q3 2021. 93 funds tracked by Wall St. Rank hold BTAI as of Q4 2021.

  • Anchor Investment Management reported no remaining BioXcel Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Anchor Investment Management sold 2 BioXcel Therapeutics shares in Q4 2021, an estimated $1.03K.
  • Anchor Investment Management first reported a position in BioXcel Therapeutics in Q3 2021 and held it in 1 quarter.
  • Anchor Investment Management's BioXcel Therapeutics position peaked at $1.03K in Q3 2021.
  • 93 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2021.

Based on Anchor Investment Management's 13F filing for Q4 2021, filed 2 Jan 2024.